Judy S. Crabtree, Ph.D., SMB(ASCP)CM

Professor of Genetics

Scientific and Education Director, Precision Medicine Program

Technical Supervisor, Precision Medicine Laboratory

533 Bolivar Street, CSRB 623A
New Orleans, LA 70112
Phone: 504-568-2963
Fax: 504-568-8500



1992  B.S. in Chemistry, University of Oklahoma

1994  M.S. in Biochemistry, University of Oklahoma

1997  Ph.D. in Biochemistry, University of Oklahoma (Advisor: Dr. Bruce A. Roe)

1997-2001 Postdoctoral Fellow, National Human Genome Research Institute, National Institutes of Health (Advisor: Dr. Francis S. Collins)

Selected Publications

NCBI My Bibliography:  https://www.ncbi.nlm.nih.gov/myncbi/judy.crabtree.1/bibliography/public/

J. Yao, E. Bergsland, R. Aggarwal, A. Aparicio, H. Beltran, J.S. Crabtree, C. Hann, T. Ibrahim, L. Byers, H. Sasano, J. Umejiego, and M. Pavel. DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms. Oncologist 27(11):940-951 (2022). PMID 35983951.

J.S. Crabtree. “Epigenetic Regulation in gastroenteropancreatic neuroendocrine tumors” in special issue on Epigenetics of Rare Cancers, Frontiers in Oncology – Cancer Genetics 12:901435 (2022). PMID: 35747820.

J. Schwartzenburg, R.Reed, H. Koul, A.H. Zea, J. Shellito, L. Miele, J.S. Crabtree, and S. Desai. ISGylation is increased in the peripheral blood mononuclear cells derived from symptomatic COVID19 patients. Experimental Biology and Medicine (Maywood) 247(10):842-847 (2022). PMID: 35130743.

S. Majumder*, J.S. Crabtree*, T.E. Golde, L. Minter, B.A. Osborne, and L. Miele. Targeting Notch in Oncology:  The Path Forward. Nature Reviews in Drug Discovery 20(2):125-144 (2021) PMID: 33293690 *equal contribution

J.S. Crabtree and L. Miele. Breast Cancer Stem Cells. Biomedicines in Special Edition “Stem Cells and Cancer Therapeutics” edited by Lluis Espinosa 6:77 (2018) 

J.S. Crabtree. Clinical and Preclinical Advances in Gastroenteropancreatic Neuroendocrine Tumor Therapy. Frontiers in Endocrinology, 8:341 (2017). 

E.C. Maggi and J.S. Crabtree. Novel Targets in the Treatment of Neuroendocrine Tumors:  RBP2.  International J. Endocrine Oncology 4(1):31-41 (2017)

J.S. Crabtree and L. Miele. Neuroendocrine tumors: current therapies, Notch signaling and cancer stem cells. J. Cancer Metastasis and Treatment 2:279-93 (2016).

E. Maggi, J. Trillo-Tinoco, A. Parker-Struckhoff, J. Vijayaraghavan, L. Del Valle and J.S. Crabtree. Retinoblastoma Binding Protein 2 (RBP2) is Frequently Expressed in Neuroendocrine Tumors and Promotes the Neoplastic Phenotype. Oncogenesis 5:e257 (2016). 

J. Vijayaraghavan, E.C. Maggi and J.S. Crabtree. miR-24 Regulates Menin in the Endocrine Pancreas. American Journal of Physiology - Endocrinology and Metabolism 307: E84-E92 (2014). 

A.S. McCampbell, H.A. Harris, J.S. Crabtree, R.C. Winneker, C.L. Walker and R.R. Broaddus.  Loss of inhibitory IRS-1 phosphorylation is an early event in mTOR-dependent growth of endometrial hyperplasia.  Cancer Prevention Research3(3): 290-300 (2010).

J.S. Crabtree*, S.A. Jelinsky*, H.A. Harris, S.E. Choe, M.M. Cotreau, M.L. Kimberland, E. Wilson, K.A. Saraf, W. Liu, A.S. McCampbell, B. Dave, R. Broaddus, E. Brown, W. Kao, J.S. Skotnicki, M. Abou-Gharbia, R.C. Winneker and C.L. Walker. Comparison of human and rat uterine leiomyomata: Identification of a dysregulated mammalian target of rapamycin pathway. Cancer Research 69(15):6171-6178 (2009).

J.S. Crabtree, B.J. Peano, X. Zhang, B.S. Komm, R.C. Winneker and H.A. Harris.  Activity of three selective estrogen receptor modulators on hormone-dependent responses in the mouse uterus and mammary gland.  Molecular and Cellular Endocrinology 287(1-2): 40-46 (2008).

J.S. Crabtree, X. Zhang, B.J. Peano, Z. Zhang, R.C. Winneker, H.A. Harris. Development of a Mouse Model of Mammary Gland versus Uterine Tissue Selectivity Using Estrogen- and Progesterone-Regulated Gene Markers. Journal of Steroid Biochemistry and Molecular Biology 101(1): 11-21 (2006).   

J.S. Crabtree, P.C. Scacheri, J.M. Ward, S.R. McNally, G.P. Swain, J.H. Hager, D. Hanahan, H. Edlund, M.A. Magnuson, L. Garrett-Beal, A.L. Burns, S.C. Chandrasekharappa, S.J. Marx, A.M. Spiegel and F.S. Collins. Of Mice and MEN1: Insulinomas in a conditional mouse knockout. Molecular and Cellular Biology 23(17): 6075-6085 (2003).

 S.K. Libutti, J.S. Crabtree, D. Lorang, A.L. Burns, C. Mazzanti, S. Hewitt, J.M. Ward, M. Emmert-Buck, A. Remaley, M. Miller, E. Turner, H.R. Alexander, A. Arnold, S.J. Marx, F.S. Collins and A.M. Spiegel. Parathyroid gland-specific deletion of the mouse Men1 gene results in parathyroid neoplasia and hypercalcemic hyperparathyroidism. Cancer Research 63(22):8022-8028 (2003).

J.S. Crabtree, P.C. Scacheri, J.M. Ward, L. Garrett-Beal, M.R. Emmert-Buck, K.A. Edgemon, D. Lorang, S.K. Libutti, S.C. Chandrasekharappa, S.J. Marx, A.M. Spiegel, and F.S. Collins. A mouse model of multiple endocrine neoplasia, type 1 develops multiple endocrine tumors. Proc. Natl. Acad. Sci, USA 98(3):1118-1123 (2001).

The Genome International Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 409(6822), 860-921 (2001). (See website supplemental information for complete author listing).

I. Dunham, N. Shimizu, B.A. Roe, S. Chissoe, et al.  The DNA Sequence of Human Chromosome 22.  Nature 402(6761):489-495 (1999). (See website for complete author listing).

S.C. Chandrasekharappa, S.C. Guru, P. Manickam, S.E. Olufemi, F.S. Collins, M.R. Emmert-Buck, L.V. Debelenko, Z. Zhuang, I.A. Lubensky, L.A. Liotta, J.S. Crabtree, Y. Wang, B.A. Roe, J. Weismann, M.S. Boguski, S.K. Agarwal, M.B. Kester, Y.S. Kim, C. Heppner, Q. Dong, A.M. Spiegel, A.L. Burns, S.J. Marx.  Positional cloning of the gene for multiple endocrine neoplasia, type 1.  Science 276(5311):404-407 (1997).